

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Ste McCon (b) (6) >

**Sent:** Wednesday, March 18, 2020 5:09 PM

**Subject:** ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf

"Clearly, the potential therapeutic utility of recombinant **ACE2 and angiotensin II receptor-inhibitors**. [ARB's ?]s—**already in clinical use for control of blood pressure**—for acute lung injury resulting from viruses and other causes will be a productive field for investigation. This is particularly relevant as we prepare to **confront a potential avian flu pandemic**, [COVID-19 ?] armed with only a limited number of therapeutic options."

Regards,

*Stephen D. McConnell, BS, MSc-CCP, CIS*

Lipidemiologist - Clinical Application Specialist

Medicare-CMS ACO/MSSP/Direct-Contracting Consultant

Medical Science Liaison

Mobile: (b) (6)

(b) (6)

Sent from my iPhone